Food-derived linear vs. rationally designed cyclic peptides as potent TNF-alpha inhibitors: an integrative...

Tumor necrosis factor-alpha (TNF-alpha) is a central mediator of chronic inflammation and a validated therapeutic target in atherosclerosis and related cardiovascular disorders. Peptide therapeutics offer high specificity and low toxicity; however, few natural sequences have been optimized for durable TNF-alpha inhibition.

A dual in silico strategy was employed to identify potent inhibitors: (i) virtual screening of experimentally validated food-derived bioactive peptides and (ii) rational design of an N-C cyclized and disulfide-bridge peptide based on the TNF-alpha-TNFR1 interface. Molecular docking, 200-ns molecular dynamics simulations, and MM/PBSA free-energy analyses were performed.

The selected peptides exhibited strong and persistent interactions with key TNF-alpha residues, particularly Tyr119. The cyclic analogue demonstrated deeper free-energy minima, higher binding affinity, and more stable hydrogen-bond networks than the linear sequence. ADMET profiling revealed superior metabolic stability, reduced plasma clearance, and no predicted cardiotoxicity.

These results indicate that dietary peptides can serve as templates for TNF-alpha inhibition, and interface-guided cyclization rationally enhances stability, binding affinity, and drug-like properties. This study provides a mechanistic framework for developing food-derived peptides as next-generation TNF-alpha antagonists and supports United Nations SDGs 3 and 9 by promoting innovative, low-toxicity therapeutics for chronic inflammation and cardiovascular diseases.